List of Excipients in Branded Drug WAKIX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Harmony Biosciences LLC	WAKIX	pitolisant hydrochloride	72028-045	CELLULOSE, MICROCRYSTALLINE	2033-02-13
Harmony Biosciences LLC	WAKIX	pitolisant hydrochloride	72028-045	CROSPOVIDONE	2033-02-13
Harmony Biosciences LLC	WAKIX	pitolisant hydrochloride	72028-045	MAGNESIUM STEARATE	2033-02-13
Harmony Biosciences LLC	WAKIX	pitolisant hydrochloride	72028-045	POLYETHYLENE GLYCOL	2033-02-13
Harmony Biosciences LLC	WAKIX	pitolisant hydrochloride	72028-045	POLYVINYL ALCOHOL	2033-02-13
Harmony Biosciences LLC	WAKIX	pitolisant hydrochloride	72028-045	SILICON DIOXIDE	2033-02-13
Harmony Biosciences LLC	WAKIX	pitolisant hydrochloride	72028-045	TALC	2033-02-13

WAKIX Excipient Strategy and Commercial Opportunities for Pitolisant

Last updated: August 9, 2026

WAKIX (pitolisant hydrochloride) is an oral, nonstimulant treatment for narcolepsy marketed by Harmony Biosciences. Its commercial formulation is a relatively conventional immediate-release tablet containing lactose, microcrystalline cellulose, crospovidone, magnesium stearate, talc, and colloidal silicon dioxide. The formulation creates limited standalone exclusivity for excipient suppliers, but meaningful opportunities exist in lactose-free reformulation, pediatric and liquid dosage forms, modified-release delivery, improved palatability, and combination products.

The strongest commercial opportunity is not a direct copy of the current tablet excipient system. It is a differentiated formulation that addresses administration, adherence, pharmacokinetics, or patient populations while avoiding dependence on Harmony's branded tablet design.

What is WAKIX and how is pitolisant formulated?

WAKIX contains pitolisant hydrochloride, a histamine H3-receptor antagonist/inverse agonist indicated in the United States for excessive daytime sleepiness or cataplexy in adults with narcolepsy. The product is supplied as immediate-release, film-coated tablets in 4.45 mg and 17.8 mg strengths, equivalent to 5 mg and 20 mg of pitolisant, respectively.[1]

WAKIX inactive ingredients

The FDA prescribing information identifies the following inactive ingredients for the tablet core:

Excipient	Likely formulation function
Lactose monohydrate	Diluent and tablet-volume builder
Microcrystalline cellulose	Compressibility and structural filler
Crospovidone	Superdisintegrant
Colloidal silicon dioxide	Glidant and moisture-flow aid
Magnesium stearate	Lubricant
Talc	Processing aid and anti-adherent

The film coating contains standard coating materials, including hypromellose, polyethylene glycol, titanium dioxide, and talc, according to the product labeling and publicly available product information.[1,2]

The excipient system indicates an immediate-release, direct-compression or closely related conventional tableting platform. The formulation is optimized for low-dose drug loading, manufacturing efficiency, rapid disintegration, and two-strength commercial scaling rather than controlled release.

What is the active pharmaceutical ingredient?

Pitolisant hydrochloride is a small-molecule oral drug. It is not a biologic and does not require biosimilar development. The principal formulation issues are likely to include dose uniformity at the lower strength, powder flow, compaction, dissolution, salt stability, and food-effect management.

What excipient strategy does WAKIX use?

WAKIX uses a standard oral solid-dose strategy with a broad, low-cost excipient base. The architecture has four commercial advantages:

1. Lactose and microcrystalline cellulose reduce manufacturing cost and support robust tablet compression.
2. Crospovidone promotes rapid tablet breakup.
3. Colloidal silicon dioxide and magnesium stearate support high-throughput tableting.
4. A film coat improves handling, appearance, swallowability, and moisture protection.

The strategy also creates potential limitations. Lactose may exclude patients with clinically relevant lactose intolerance or create a labeling issue for consumers seeking lactose-free medicines. Magnesium stearate and talc are widely accepted but can affect powder flow, lubricant sensitivity, dissolution, and process robustness. The current dosage form also depends on swallowing an intact tablet, which limits use in patients with dysphagia, pediatric populations, and patients who need administration through enteral feeding systems.

What formulation patents protect WAKIX?

Publicly available regulatory materials identify the marketed drug and its excipients, but the label alone does not establish a separate, enforceable patent estate for each excipient or for the complete commercial formulation. Patent protection must be assessed by claim scope, expiration, prosecution history, Orange Book listing, and litigation status.

Which patent categories matter for WAKIX?

The relevant patent categories are:

• Pitolisant composition-of-matter patents.
• Salt, polymorph, crystal-form, or solid-state patents.
• Tablet formulation patents.
• Manufacturing-process patents.
• Method-of-use patents covering narcolepsy, excessive daytime sleepiness, or cataplexy.
• Pediatric, liquid, orally disintegrating, or modified-release formulations.
• Combination-treatment patents.
• Drug-device or administration-system patents.

A generic applicant may design around a formulation patent while still challenging listed patents through an abbreviated new drug application and Paragraph IV certification. A formulation patent is commercially important only if its claims cover a feature that a competitive product is likely to use and if the patent remains enforceable through the relevant launch period.

What is the Orange Book status of WAKIX?

WAKIX is approved under an FDA new drug application and is subject to the FDA's listed-drug framework. Orange Book analysis should distinguish between:

• Patents listed against WAKIX;
• Regulatory exclusivity associated with the approval;
• Unlisted patents that may still affect litigation or commercial risk;
• Patents covering uses that an ANDA applicant may omit through a section viii statement.

The current FDA Orange Book should be used for a live patent-number and expiration-date review. A static product label does not provide a complete patent table. The Hatch-Waxman risk profile depends on the exact listed patent set at the time of an ANDA filing, not only on patents cited in historical publications.[3]

When does WAKIX lose exclusivity?

WAKIX received FDA approval on Aug. 14, 2019.[4] Pitolisant had prior marketing history outside the United States, which affects the availability of certain U.S. regulatory exclusivities. The key commercial dates are therefore driven by the patent estate, orphan-drug exclusivity, pediatric extensions, and any later-approved protected indications.

Harmony Biosciences has described WAKIX as having orphan-drug protection associated with narcolepsy. U.S. orphan-drug exclusivity generally lasts seven years from approval for the protected indication, subject to the statutory framework and the specific scope of the designation.[5] On that basis, the original narcolepsy exclusivity period would reach approximately August 2026, absent a different designation or regulatory calculation.

WAKIX exclusivity timeline

Event	Date or period	Commercial relevance
FDA approval of WAKIX	Aug. 14, 2019	U.S. launch approval
Orphan-drug exclusivity	Approximately through Aug. 2026	Blocks approval of the same drug for the same protected indication, subject to statutory exceptions
Patent expiry	Patent-specific	May extend beyond regulatory exclusivity
Pediatric exclusivity	Patent- or exclusivity-specific	Could add six months if granted
Generic launch	Depends on ANDA, patents, litigation, and settlement	Earliest date is not determined by orphan exclusivity alone

The commercial market could therefore remain protected after the orphan period if valid patents cover pitolisant, the formulation, a manufacturing process, or a protected use.

What generic entry risks exist for WAKIX?

The principal generic risks are conventional tablet substitution and indication carve-outs.

A generic applicant could reproduce the immediate-release tablet using different excipients if it demonstrates pharmaceutical equivalence, bioequivalence, stability, and acceptable quality attributes. The applicant would not necessarily need to use lactose, crospovidone, or magnesium stearate. This makes the excipient system a relatively weak barrier unless a patent claims a specific excipient ratio, dissolution profile, particle-size distribution, solid form, or manufacturing process.

How could a generic challenge WAKIX?

Potential pathways include:

• Paragraph III certification to wait for patent expiration.
• Paragraph IV certification alleging that listed patents are invalid, unenforceable, or not infringed.
• Section viii labeling that omits patented indications.
• A 505(b)(2) application for a differentiated dosage form, liquid, or modified-release product.
• A direct commercial challenge after regulatory exclusivity expires.

A first-filer Paragraph IV applicant could receive 180-day generic exclusivity if statutory requirements are satisfied. That could delay broad generic competition while creating a high-value settlement negotiation with Harmony.

What patent litigation affects WAKIX?

The principal litigation risk is likely to center on listed patents and any patents asserted against ANDA applicants, rather than on individual commodity excipients. A proper review requires the current Orange Book, FDA patent-listing records, district-court dockets, and Federal Circuit decisions.

No reliable business conclusion should treat the presence of a particular excipient in the WAKIX label as evidence that a generic cannot substitute another excipient. FDA approval is based on product equivalence and performance, not identical inactive ingredients in every case.

What excipient opportunities exist for WAKIX?

Lactose-free WAKIX formulation

A lactose-free tablet is the most straightforward reformulation opportunity. Lactose could be replaced with mannitol, anhydrous dibasic calcium phosphate, spray-dried mannitol, starch, or a co-processed filler. The commercial value would depend on whether the product could support a clinically meaningful claim, improved tolerability, or broader institutional procurement.

A lactose-free formulation could also reduce dependence on dairy-derived supply chains and simplify positioning for patients who avoid lactose-containing products.

Orally disintegrating tablet

An orally disintegrating tablet could target patients with dysphagia, irregular schedules, or difficulty taking medication during daytime activities. Suitable platforms include mannitol-based orally disintegrating systems, crospovidone or croscarmellose disintegration technologies, and taste-masking coatings or polymeric particles.

The key technical risks are pitolisant bitterness, dose uniformity, moisture sensitivity, friability, and the need to demonstrate rapid dispersion without compromising bioavailability.

Oral liquid or powder-for-reconstitution

A liquid or sachet product could expand use in pediatric narcolepsy, patients with swallowing impairment, and patients receiving medication through feeding tubes. The development burden would include:

• Pitolisant solubility and salt stability;
• Chemical and microbiological stability;
• Preservative selection;
• Container-closure compatibility;
• Dosing-device accuracy;
• Taste masking;
• In-use stability;
• Enteral-tube adsorption and recovery.

A liquid formulation may be more valuable than an excipient-only change because it creates a distinct dosage form and could support a new regulatory strategy.

Modified-release formulation

Pitolisant has a daily dosing schedule in the approved U.S. product. A modified-release formulation could target smoother exposure, reduced peak-related adverse effects, or improved adherence. Technologies could include hydrophilic matrix tablets, multiparticulates, coated pellets, osmotic systems, or gastroretentive platforms.

The commercial case is weaker if once-daily dosing already provides adequate adherence and tolerability. A modified-release product would need a measurable clinical or pharmacokinetic benefit and could trigger new bioequivalence and clinical-development requirements.

Sprinkle or enteral administration

A capsule containing coated multiparticulates or a granule product could permit administration with soft food or through an enteral tube. The platform would require protection against chewing, dose loss, moisture uptake, and food interaction. This product could compete less directly with a standard tablet and may receive stronger formulation protection if the dosage form is technically differentiated.

How strong is the WAKIX formulation patent estate?

The formulation patent estate appears strategically more important than the public excipient list itself, but strength depends on claim construction and remaining term. A strong estate would claim a difficult-to-design-around combination such as:

• A defined pitolisant solid form;
• A narrow particle-size distribution;
• A specific dissolution profile;
• A defined excipient ratio;
• A manufacturing sequence that controls content uniformity;
• A liquid or orally disintegrating dosage form;
• A formulation linked to a pharmacokinetic or tolerability advantage.

A weak estate would claim broad conventional tablet ingredients without a demonstrated technical effect. Generic applicants can often replace one filler, lubricant, glidant, or disintegrant while retaining equivalent performance.

Manufacturing and intellectual-property barriers

Manufacturing barriers may be more practical than excipient patents. These include:

• Controlling low-dose content uniformity;
• Managing powder segregation;
• Achieving reproducible dissolution;
• Controlling residual moisture;
• Producing consistent film coating;
• Maintaining stability across packaging configurations;
• Scaling tablet compression without capping or picking.

Such barriers can slow competitive development but do not create the same exclusionary effect as a valid patent. They can, however, strengthen trade-secret protection around process parameters and supplier qualification.

What licensing deals could create commercial value?

The most credible licensing opportunities involve differentiated delivery rather than commodity excipient supply. Potential counterparties include:

• Excipients companies with co-processed direct-compression fillers;
• Taste-masking specialists;
• Orally disintegrating tablet technology providers;
• Multiparticulate and enteric-coating companies;
• Pediatric liquid-formulation developers;
• Drug-device companies with dosing systems;
• Contract development and manufacturing organizations.

A licensing transaction could involve an exclusive field-of-use license for a pediatric liquid, an orally disintegrating tablet, or an enteral formulation. A supplier agreement for ordinary lactose or magnesium stearate would likely have limited strategic value unless it includes a novel grade, supply exclusivity, or process know-how.

How does WAKIX compare with competing narcolepsy therapies?

WAKIX competes with stimulants, sodium oxybate products, and wake-promoting agents. Its nonstimulant mechanism and once-daily oral tablet create a different commercial profile from controlled substances and liquid nighttime therapies.

Product category	Dosage-form opportunity	Excipient opportunity
WAKIX pitolisant	Immediate-release tablet	Lactose-free, ODT, liquid, modified release
Modafinil/armodafinil	Conventional tablets	Generic cost competition and formulation differentiation
Sodium oxybate products	Oral liquid	Palatability, dosing accuracy, abuse-deterrence systems
Solriamfetol	Immediate-release tablet	Dose flexibility, swallowability, modified release
Stimulants	Tablets, capsules, liquids	Abuse-deterrent and pediatric delivery systems

WAKIX has greater opportunity for lifecycle management than a mature generic stimulant if Harmony can protect a differentiated dosage form before broad generic entry.

What is the revenue exposure from generic WAKIX entry?

WAKIX revenue is concentrated in the narcolepsy market, making generic entry economically significant even if the absolute patient population is smaller than mass-market therapies. Harmony has reported WAKIX as its principal commercial product, so loss of exclusivity would affect company-level revenue disproportionately.[6]

The impact would depend on:

• Number of approved ANDAs;
• Whether the first generic is authorized for all or only some indications;
• Reimbursement substitution;
• Net price reductions;
• Patient switching;
• Pharmacy benefit-manager policies;
• Persistence of branded clinical preference;
• Availability of differentiated branded formulations.

A successful pediatric, liquid, or orally disintegrating product could preserve premium pricing in segments that are less exposed to ordinary tablet substitution.

Key Takeaways

• WAKIX is a conventional immediate-release pitolisant tablet using lactose, microcrystalline cellulose, crospovidone, colloidal silicon dioxide, magnesium stearate, and talc.
• The current excipient list is unlikely to create a substantial barrier by itself.
• The highest-value opportunities are lactose-free, orally disintegrating, liquid, sprinkle, enteral, and modified-release formulations.
• WAKIX was approved by the FDA on Aug. 14, 2019, with orphan-drug protection expected to be commercially relevant through approximately August 2026 for the protected narcolepsy indication.
• Generic applicants can usually design around conventional excipient selections if they meet equivalence and quality requirements.
• Stronger intellectual-property positions would claim solid state, dissolution, particle engineering, dosage-form architecture, manufacturing controls, or a demonstrated pharmacokinetic advantage.
• Harmony's revenue exposure is material because WAKIX is its core commercial product.
• The most attractive licensing targets are differentiated delivery technologies, not commodity excipient supply.

FAQs

Can a generic WAKIX use different excipients?

Yes. A generic applicant may use different inactive ingredients if the product satisfies FDA requirements for pharmaceutical equivalence, bioequivalence, quality, safety, and labeling.

Is WAKIX lactose-free?

No. The U.S. WAKIX tablet contains lactose monohydrate.[1]

Could a lactose-free pitolisant tablet receive separate patent protection?

Yes. Protection could be available if the formulation claims are novel, non-obvious, enabled, and adequately supported. A mere substitution of lactose with another standard filler may face an obviousness challenge.

Is pitolisant suitable for a pediatric liquid formulation?

A pediatric liquid would require separate formulation and regulatory development. The principal technical challenges are solubility, taste, stability, dosing accuracy, and compatibility with administration devices.

Are biosimilars a risk for WAKIX?

No. Pitolisant is a small-molecule drug, so competitive products would proceed through generic or other small-molecule regulatory pathways rather than the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2024). WAKIX (pitolisant hydrochloride) tablets: U.S. prescribing information. Harmony Biosciences, LLC. https://www.accessdata.fda.gov/drugsatfda_docs/label/

2. European Medicines Agency. (2023). Wakix: Product information. https://www.ema.europa.eu/en/medicines/human/EPAR/wakix

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2019, August 14). FDA approves new treatment for excessive daytime sleepiness in adult patients with narcolepsy. https://www.fda.gov/

5. U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity. https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/orphan-drug-designation-and-exclusivity

6. Harmony Biosciences Holdings, Inc. (2024). Annual report on Form 10-K. U.S. Securities and Exchange Commission. https://www.sec.gov/edgar/browse//?CIK=1802667